Noninvasive predictive models of liver fibrosis in patients with chronic hepatitis B

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 961-971

  Wan, Ruijie ^a   Liu, Huimin ^a   Wang, Xianbo ^a   Wan, Gang ^b   Wang, Xiaojing ^a   Zhou, Guiqin ^a   Jiang, Yuyong ^a   Sun, Fengxia ^a   Yang, Zhiyun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hepatitis B virus; Liver fibrosis; Model; Noninvasive diagnosis; Receiver operating characteristic (ROC) curve

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; GAMMA GLUTAMYLTRANSFERASE; GLOBULIN; HEMOGLOBIN; HEPATITIS B (E) ANTIGEN; PROTHROMBIN; UNCLASSIFIED DRUG;

ADULT; APAG INDEX; ARTICLE; BLOOD CELL COUNT; BODY MASS; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; IMMUNOREACTIVITY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEASUREMENT ACCURACY; NON INVASIVE PROCEDURE; PREDICTIVE VALUE; PROCESS MODEL; RECEIVER OPERATING CHARACTERISTIC; S INDEX; SENSITIVITY AND SPECIFICITY; WANG I INDEX; WANG II INDEX; ZENG MODEL;

HEPATITIS B VIRUS;

EID: 84923025847     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A and Bedossa P. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003; 38: 257-265.
2. Ganem D and Prince AM. Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
3. World Health Organization. Hepatitis B (Revi-sed August 2008).
4. Rockey DC and Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006; 43: S113-120.
5. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20: 15-20.
6. Bedossa P, Dargere D and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457.
7. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, Reddy KR and Schiff ER. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618.
8. Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D and Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525.
9. Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y and Ratziu V. Assessment of liver fibrosis: noninvasive means. Saudi J Gastroenterol 2008; 14: 163-173.
10. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM and Rodes J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepa-tology 2002; 36: 986-992.
11. Kim BK, Kim SA, Park YN, Cheong JY, Kim HS, Park JY, Cho SW, Han KH, Chon CY, Moon YM and Ahn SH. Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int 2007; 27: 969-976.
12. Chung IK, Lee JH, Lee SH, Kim SJ, Cho JY, Cho WY, Hwangbo Y, Keum BR, Park JJ, Chun HJ, Kim HJ, Kim JJ, Ji SR and Seol SY. Therapeutic outcomes in 1000 cases of endoscopic submucosal dissection for early gastric neoplasms: Korean ESD Study Group multicenter study. Gastrointest Endosc 2009; 69: 1228-1235.
13. Shaheen AA and Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepa-tology 2007; 46: 912-921.
14. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y and Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357: 1069-1075.
15. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A and Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005; 42: 1373-1381.
16. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW and Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51: 1867-1873.
17. Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, Mao YM, Zeng MD and Lu LG. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010; 25: 1569-1577.
18. Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF and Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. Hepatology 2005; 42: 1437-1445.
19. Hui AY, Chan HL, Wong VW, Liew CT, Chim AM, Chan FK and Sung JJ. Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol 2005; 100: 616-623.
20. Mohamadnejad M, Montazeri G, Fazlollahi A, Zamani F, Nasiri J, Nobakht H, Forouzanfar MH, Abedian S, Tavangar SM, Mohamadkhani A, Ghoujeghi F, Estakhri A, Nouri N, Farzadi Z, Najjari A and Malekzadeh R. Noninvasive markers of liver fibrosis and inflammation in chronic hepatitis B-virus related liver disease. Am J Gastroenterol 2006; 101: 2537-2545.
21. Fung J, Lai CL, Fong DY, Yuen JC, Wong DK and Yuen MF. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis. Liver Int 2008; 28: 1408-1416.
22. Croagh CM, Bell SJ, Slavin J, Kong YX, Chen RY, Locarnini S and Desmond PV. Increasing hepatitis B viral load is associated with risk of significant liver fibrosis in HBeAg-negative but not HBeAg-positive chronic hepatitis B. Liver Int 2010; 30: 1115-1122.
23. Tran TT. Immune tolerant hepatitis B: a clinical dilemma. Gastroenterol Hepatol (N Y) 2011; 7: 511-516.
24. Lok AS and McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
25. Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis 2003; 23: 47-58.
26. McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis 2004; 24 Suppl 1: 17-21.
27. Hoofnagle JH, Doo E, Liang TJ, Fleischer R and Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45: 1056-1075.
28. Lok AS and McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539.
29. Hadziyannis SJ and Papatheodoridis GV. Hepa-titis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis 2006; 26: 130-141.
30. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
31. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2012; 57: 167-185.
32. Wong GL, Wong VW, Choi PC, Chan AW and Chan HL. Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Phar-macol Ther 2010; 31: 1095-1103.
33. Swets JA. Measuring the accuracy of diagnostic systems. Science 1988; 240: 1285-1293.
34. Poynard T and Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat 1997; 4: 199-208.
35. Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of “hypersplenic” thrombocytopenia. J Clin Invest 1966; 45: 645-657.
36. Jiao YF, Okumiya T, Saibara T, Kudo Y and Sugiura T. Erythrocyte creatine as a marker of excessive erythrocyte destruction due to hypersplenism in patients with liver cirrhosis. Clin Biochem 2001; 34: 395-398.
37. Li XM, Ma L, Yang YB, Shi ZJ and Zhou SS. Analyses of prognostic indices of chronic liver failure caused by hepatitis virus. World J Gastroenterol 2005; 11: 2841-2843.
38. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y and Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol 2003; 39: 222-230.
39. Ruhl CE and Everhart JE. Elevated serum alanine aminotransferase and γ-glutamyltrans-ferase and mortality in the United States population. Gastroenterology-Orlando 2009; 136: 477.
40. Giannini E, Ceppa P, Botta F, Fasoli A, Roma-gnoli P, Cresta E, Venturino V, Risso D, Celle G and Testa R. Steatosis and bile duct damage in chronic hepatitis C: distribution and relationships in a group of Northern Italian patients. Liver 1999; 19: 432-437.
41. Bressler BL, Guindi M, Tomlinson G and Heathcote J. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 2003; 38: 639-644.
42. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G and Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroen-terology 2004; 126: 586-597.
43. James OF and Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998; 29: 495-501.
44. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS and Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
45. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M and Palau R. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.